Introduction
There is increasing evidence that chronic HIV infection is associated with an elevated risk of coronary heart disease [1, 2] . The risk persists after adjustment for traditional risk factors and may be partially attributed to inflammation and residual immune dysregulation despite effective antiretroviral therapy (ART) [3] [4] [5] . The mechanisms of immune dysregulation in treated HIV infection are complex and include activation of the innate and adaptive immune system resulting from low-level viral replication [6] , adipose tissue dysfunction [7] , coinfections such as cytomegalovirus [8] and translocation of microbial products from a damaged gut [9] . Recent studies suggest that T-cell activation [10] [11] [12] and monocyte activation [13] [14] [15] [16] are associated with vascular disease in HIVinfected patients.
Coronary artery calcification (CAC) detected by computed tomography (CT) is an accepted surrogate marker of coronary atherosclerosis that provides superior cardiovascular disease (CVD) risk discrimination than other surrogate markers in the general population [17] . A meta-analysis of older studies found no association of HIV infection with presence of CAC (pooled odds ratio 0.95) [18] , though recent studies suggest that treated HIV-infected patients have higher calcium scores than matched controls [19, 20] . Interestingly, HIV infection also appears to be associated with more noncalcified atherosclerotic plaque by CT angiography [16] , suggesting that CAC alone may not detect the true burden of disease in this population. This is supported by another study in which over one-third of HIV-infected patients without detectable CAC had carotid atherosclerosis by ultrasound [20] .
Biomarkers of more generalized inflammation such as high-sensitivity C-reactive protein (hs-CRP) or interleukin-6 (IL-6) are strongly predictive of CVD events but are only weakly associated with CAC in the general population [21, 22] , suggesting that generalized inflammation may influence CVD risk primarily through alternative mechanisms (i.e. plaque rupture and thrombosis). In the HIV-infected population, biomarkers of generalized inflammation are strongly predictive of cardiovascular events [5] , but these biomarkers have not been related to coronary calcification in published studies [16, 19] .
In this study, we therefore aimed, for the first time in HIV, to comprehensively examine the relationship of biomarkers of inflammation, T-cell activation and monocyte activation with CAC in a population of HIV-infected patients on modern ART. We further hypothesized that among patients with and without coronary artery calcium, these biomarkers would be related to the extent of subclinical disease in other vascular beds.
Materials and methods

Study design
This study is a cross-sectional analysis of 147 HIV-infected adults on ART who underwent comprehensive cardiometabolic risk assessment and immunophenotyping at the time of enrolment into the Stopping Atherosclerosis and Treating Unhealthy bone with RosuvastatiN in HIV (SATURN-HIV) trial. SATURN-HIV is a randomized, double-blind, placebo-controlled trial designed to measure the effect of rosuvastatin 10 mg daily on the progression of subclinical vascular disease. All individuals were at least 18 years of age, on stable ART for at least 12 weeks with HIV-1 RNA less than 1000 copies/ml, without known coronary disease or diabetes, no statin intake for at least the last 6 months and with a fasting lowdensity lipoprotein cholesterol (LDL-C) of 130 mg/dl or less. Additional entry criteria included evidence of heightened T-cell activation (CD8þCD38þHLA-DRþ !19%) and/or increased inflammation (hs-CRP !2 mg/l). The study was approved by the Institutional Review Board of University Hospitals Case Medical Center (Cleveland, Ohio, USA) and written informed consent was obtained from each study participant.
Study evaluations
Self-reported demographics and medical history were obtained along with a targeted physical examination, including height, weight, waist and hip measurements. Blood was drawn after at least a 12-h fast for glucose, insulin and lipoproteins. HOMA-IR was calculated from the fasting glucose and insulin measurements [23] . Ten-year Framingham Risk Score and Reynold's Risk Score were calculated using published risk calculators [24] [25] [26] . HIV-1 RNA level and CD4 þ cell count were obtained as part of routine clinical care. Trunk and limb fat were measured by whole-body dual-energy absorptiometry (DEXA) [27] . Epicardial and peri-aortic fat were measured by CT [10] .
Coronary artery calcium score All individuals had a baseline CT scan of the chest to quantify CAC burden. A 64-slice multidetector CT scanner (Somatom Sensation 64; Siemens Healthcare, Malvern, Pennsylvania, USA) was used with 30 Â 0.6 mm collimation, 330 ms rotation time and 120 kV tube voltage. Three-millimetre slices were obtained from the carina to the diaphragm with prospective ECG gating at 60% of the R-R interval. Calcified coronary lesions were defined as areas of at least 6 pixels with density more than 130 Hounsfield units (HU). A single reader (R.G.) quantified total coronary calcium score using the Agatston method.
Immune activation and inflammation markers Soluble plasma biomarkers of monocyte activation (soluble CD14 and CD163), systemic inflammation [hs-CRP, IL-6, tumour necrosis factor-a receptor I Monocyte and T-cells were phenotyped by flow cytometry as previously described [10, 28] . CD4 þ and CD8 þ T-cell activation was defined as coexpression of CD38 and HLA-DR. Monocyte phenotype was determined by the relative expression of CD14, CD16 and surface tissue factor (TF).
Vascular ultrasound
A high-resolution B-mode ultrasound scan of the carotid arteries was performed using a Philips iU22 ultrasound system with an L9-3 MHz linear array transducer according to the consensus protocol of the American Society of Echocardiography [29] . Mean-mean and mean-max common carotid artery intima-media thickness (CCA-IMT) were measured as described previously [10] . Complete scans of the bilateral common carotid arteries (CCAs), internal carotid arteries (ICAs) and external carotid arteries (ECAs) were used to identify plaque, defined as IMT greater than 1.5 mm or more than 50% thicker than the adjacent vessel. Carotid atherosclerosis was defined as the presence of plaque or a meanmax CCA-IMT greater than 1.0 mm.
Brachial artery reactivity testing was performed using the same L9-3 MHz transducer and 5-min occlusion time according to a previously described AIDS Clinical Trials Group protocol [30] with omission of nitroglycerinmediated dilation testing. Flow-mediated dilation (FMD) of the brachial artery was calculated as the percentage change in brachial artery diameter from baseline to 60 s postreactive hyperemia. The average velocity-time integral (VTI) of the third, fourth and fifth beats of reactive hyperemic flow after cuff release was used as a measure of microvascular function. Abnormal endothelial function was defined as having below median values of both FMD (<4%) and hyperemic VTI (<77 cm).
All vascular ultrasound measurements were performed offline by a single reader (C.T.L.) using semi-automated edge detection software (Medical Imaging Applications LLC, Coralville, Iowa, USA).
Statistical analysis
Baseline characteristics of participants were described using medians and interquartile ranges for continuous variables and frequencies and percentages for categorical ones. These characteristics were compared between the CAC present and absent groups using Wilcoxon signed rank tests or chi-square tests, as appropriate. The Wilcoxon test was also utilized to compare median values of biomarkers of inflammation and immune activation in the two CAC groups. Differences among median values of sCD14 in three CAC groups were assessed using the Kruskal-Wallis test. Correlations between biomarkers with measures of vascular structure and function in patients with and without detectable CAC levels were assessed using Spearman's rho. The probability of CAC greater than 0 was modelled as a function of sCD14 and other covariates using binary multivariable logistic regression.
The overlap of coronary atherosclerosis (CAC >0), carotid atherosclerosis (plaque in any carotid vessel or mean-max CCA-IMT >1 mm) and endothelial dysfunction (FMD and hyperemic VTI both <75th percentile) was visually described using a Venn diagram. Participants with detectable coronary calcium were further compared with normal individuals by categorizing the participants into five groups (i.e. vascular disease phenotypes). These five ordered groups represent an increasing burden of vascular disease from normal (Group 1) to extensive subclinical disease involving multiple vascular beds (Group 5). Linear regression was used to analyse the trend of five biomarkers of interest across the five ordered groups.
All statistical tests were two-sided with a 0.05 significance level. Nominal P values are presented throughout. Analyses were performed with SAS version 9.2 (SAS Institute, Cary, North Carolina, USA).
Results
The baseline characteristics of study participants are displayed in Table 1 . Overall, median age was 46 years. Three-quarters of participants were men, and two-thirds were African-American. Median time since HIV diagnosis was 12 years, and median current CD4 þ T-cell count was 613 cells/ml; 50% were currently on protease-inhibitor based ART, but only 5% were currently taking a thymidine analogue. Median 10-year Framingham Risk Score was 3.0% and Reynold's Risk Score was 2.1%. Compared with those without detectable coronary calcium, participants with CAC greater than 0 were older, less commonly African-American and had higher current CD4 þ T-cell counts and lower nadir CD4 þ cell counts. They had higher concentration of LDL-C and global risk scores but had similar indices of insulin sensitivity and prevalence of metabolic syndrome [31] . Ectopic fat volumes were higher among those with CAC greater than 0 and there was a trend towards lower limb adipose tissue volumes (P < 0.1).
Biomarkers of inflammation and immune activation were generally similar between participants with and without detectable CAC, with two exceptions (Table 2) . Soluble CD14 concentration was higher and TF expression on inflammatory (CD14 þ CD16 þ ) monocytes was lower among those with CAC greater than 0. When participants were further stratified into three categories, there was a graded increase in sCD14 [median (IQR) 2057 (1677-2413), 2212 (1914-2469) and 2504 (1956-2918) ng/ml for CAC 0, CAC 1-99 and CAC >100, respectively; P ¼ 0.017]. This statistically significant relationship between sCD14 and CAC >0 persisted (P ¼ 0.028) in a multivariable logistic regression model that adjusted for age, sex, race, nadir CD4 þ cell count, LDL-C and limb fat.
The associations of biomarkers of inflammation and immune activation with ultrasound-derived measures of vascular disease differed according to whether CAC was present or absent (Table 3) . For example, CD4
þ and CD8 þ T-cell activation was associated with CCA-IMT only among those without coronary calcium. Despite the lack of a relationship with FMD, higher levels of inflammation were consistently associated with worse microvascular function as measured by hyperemic VTI among those with and without CAC.
Over two-thirds of our cohort had some degree of subclinical atherosclerosis or endothelial dysfunction and nearly one in 10 had evidence of extensive vascular disease in all three vascular territories (Fig. 1) . coronary calcification alone, patients with increasing extent of subclinical disease in addition to CAC had higher levels of sCD14 and other biomarkers of inflammation (Fig. 2) . The 13 participants with the most extensive vascular disease consistently had the highest levels of inflammation and immune activation.
Discussion
We have demonstrated in this cross-sectional study of a comprehensively phenotyped cohort of HIV-infected patients treated with modern ART that inflammation and immune activation correlates to the extent of vascular disease in multiple vascular beds. Soluble CD14, a surrogate of monocyte activation, is a particularly strong marker of the extent of subclinical vascular disease. Our finding that vascular disease is common but heterogeneous in this population is an important guiding principle for the design and interpretation of future studies of CVD risk in HIV.
CD14 is a coreceptor on innate immune cells that, together with Toll-like receptor-4 and lipopolysaccharide (LPS)-binding protein, allows these cells to scavenge
circulating bacterial LPS and releases nuclear factor-kB dependent inflammatory cytokines [32] . The soluble form of CD14 (sCD14) is shed by activated monocytes and has been proposed as a surrogate marker of LPSinduced activation [9] , although the liver also produces sCD14 as an acute phase protein in response to IL-6 [33] .
Soluble CD14 and coronary calcium in HIV Longenecker et al. 973 Table 2 . Biomarkers of inflammation and immune activation by coronary artery calcium category. Data presented as median (interquartile range). CRP, C-reactive protein; OPG, osteoprotegerin; RANKL, receptor activator of nuclear factor kappa-B ligand; TNF, tumour necrosis factor; VCAM, vascular cell adhesion molecule. Table 3 . Correlations of biomarkers with measures of vascular structure and function stratified by coronary artery calcium status. Plasma sCD14 and LPS are elevated in chronic HIV infection and are associated with poor immunologic response to ART [34] , progression of HIV-1 [35] and HIV-2 [36] disease, and mortality [37, 38] .
CCA-IMT
In the general population, plasma sCD14 levels have recently been independently associated with myocardial infarction, coronary heart disease and all-cause mortality among older (>65 years) men and women in the Cardiovascular Health Study (CHS) [39] . Several genome-wide single-nucleotide polymorphisms (SNPs) explain about one-third of the variance of sCD14 in this population; however, none of these SNPs was associated with mortality or cardiovascular disease after adjustment for multiple testing. Genetic polymorphisms that increase sCD14 have been variably associated with coronary heart disease in several other cohorts [32, 40, 41] . Similar to our findings, soluble CD14 was also associated with subclinical vascular disease as measured by carotid IMT or ankle-brachial index in CHS [39] . In the European PRIME study, sCD14 was not associated with CVD events despite correlations with other biomarkers of inflammation, endothelial activation and coagulation [42] .
This is the first published study to demonstrate a relationship between sCD14 and CAC in HIV-infected patients that is independent of traditional risk factors. This is in agreement with two other studies that have associated sCD14 levels with both pathologic carotid IMT thickening [43] and progression of IMT over time [13] . A large number of other studies, however, have failed to demonstrate an association between sCD14 and carotid disease [10, 44] , endothelial function [45] and coronary atherosclerosis in men [15, 16] . In a study of HIV-infected women, sCD14 levels were significantly elevated compared with controls, but did not appear to be associated with number or types of coronary plaque [46] . Interestingly, these same studies have variably shown associations of vascular disease with LPS [45] or other markers of monocyte activation such as soluble CD163 [15, 16, 46] .
Although this study lacked a HIV-negative control group, the magnitude of plasma sCD14 levels observed among study participants with increasing extent of subclinical vascular disease can be placed in the context of HIVuninfected controls from our laboratory and the general population using the same assay. Mean concentrations of three HIV-uninfected control populations from our laboratory ranged from 1340 to 1740 ng/ml [47] [48] [49] .
In the CHS, mean (SD) concentration was 1641 (348) ng/ml [39] . In the present study, mean sCD14 of patients in Group 5 (CAC>0 and endothelial dysfunction and carotid disease; mean sCD14 2495 ng/ml) was elevated but equal to the approximate upper bound of normal in the CHS (1.5Â the interquartile range above the 75th percentile) [39] .
Together with this previous literature, our data suggest that even modest amounts of chronic monocyte activation may contribute to the development of subclinical atherosclerosis in treated HIV infection. In addition, monocyte activation may trigger acute vascular events through alternative pathways (i.e. thrombosis) [28, 50] , though this study was not designed to evaluate that hypothesis. In light of early data from SATURN-HIV suggesting that rosuvastatin effectively reduces sCD14 [51] , we are particularly optimistic about the potential for statins to reduce CVD risk in patients with residual immune activation despite ART.
Hsue et al. [20] have previously described the extent of carotid disease in patients with and without coronary artery calcium. Our study confirms the finding that 30-50% of HIV-infected patients without detectable coronary calcium have subclinical carotid disease. We agree that this may represent an earlier stage of atherosclerosis that is mediated by different pathways. For example, although Tcell activation is known to be associated with carotid disease [10] [11] [12] , our data suggest that this relationship is strongest among those who have not yet developed detectable coronary calcium (i.e. earlier stage atherosclerosis). Our data also suggest that microvascular function measured by hyperemic VTI -in contrast to FMD -is correlated with systemic inflammation markers such as interleukin-6 and may add significantly to CVD risk prediction in patients with CAC scores of zero. In the general population, hyperemic VTI, but not FMD, is predictive of CVD events in an otherwise low-risk population [52] .
Our study also highlights the utility of multimodality imaging for the evaluation of CVD risk. To our knowledge, ours is the first study to combine endothelial function testing together with carotid ultrasound and CAC scoring as a measure of the extent of vascular disease in the HIV-infected population. This method elucidates relationships that may otherwise go undetected. For example, although sCD14 was not associated with carotid disease in an initial analysis of this cohort [10] and was not correlated with ultrasound measures of vascular disease in this current study (Table 3) , a combined measure of the extent of vascular disease showed a clear relationship with sCD14 ( Fig. 2) . This could be replicated in larger HIVinfected cohort studies that have measured CAC, carotid IMT and brachial endothelial function in the same participants, although long-term follow-up will be required to determine the prognosis of the various subclinical vascular disease phenotypes. In addition, a combined vascular endpoint may be useful in trials of interventions that aim to reduce CVD risk by reducing inflammation in this population.
Limitations
The overall study size was robust considering the extensive characterization of the study participants; however, we may have lacked power to detect minor relationships within the subgroup analyses. Our study also shares the limitations of all cross-sectional analyses, including the possibility of residual confounding and inability to determine causality. Because this study investigated a specific HIV-infected population with normal LDL-C, the generalizability to the HIV-infected population with high lipid levels should be determined in future studies. Finally, the large number of statistical comparisons raises the risk of type-I error.
Conclusion
Soluble CD14 is independently associated with CAC, and, among those with detectable calcium, predicts the extent of subclinical disease in other vascular beds.
Similarly, other biomarkers of inflammation and immune activation may be associated with ultrasound measures of vascular disease in patients without detectable CAC. A combined multimodality measure of vascular disease phenotypes may help elucidate the pathophysiology of atherosclerosis in HIV-infected patients on ART and could serve as a useful endpoint in trials that aim to reduce CVD risk in this population. 
